WORLD-ANTI-SMOKING-PLCY
3.4.2024 07:01:29 CEST | Business Wire | Press release
We Are Innovation, a leading global innovation network, released the 2024 Effective Anti-Smoking Policies Global Index (https://antismoking.global/). The index assesses around 5.5 billion people, nearly 70 percent of the world's population. It offers an analysis of the public policies to eradicate smoking in 69 countries across four regions. The Index delves into the intricacies of alternative nicotine products, scrutinizing aspects such as regulatory frameworks, prohibitions, taxation, and governmental measures for switching from smoking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402477735/en/
The top 20 countries in the global anti-smoking index, led by the United Kingdom, Sweden, and Slovakia in the podium positions, collectively impact almost 1 billion people worldwide. European nations dominate the list, with 15 out of the 20 spots occupied by countries from this region. However, non-European nations like the United States, Lebanon, New Zealand, Canada, and Saudi Arabia also make significant strides in terms of regulations.
The index emphasizes the urgent need for global advancements in anti-smoking policies. Finding a balance between traditional measures and innovative approaches, including alternative nicotine products, is key to success. The Index calls for a holistic approach encompassing alternative products to address the gaps in regulation.
Global policies differ radically in receptiveness, with vaping facing sales bans despite growing evidence on its harm reduction. Thus, seventeen countries have prohibited vaping. Tobacco Heated Products (THP) policies show similar regional bifurcation patterns. Thirteen countries prohibit THP, mostly in South America and Asia. Snus faces widespread prohibitions in the European Union, except in Sweden. China with bans on THP and nicotine pouches and heavy restriction of vaping and snus scored 51st place. India scored last globally for completely prohibiting all nicotine alternatives. In addition to forgoing harm reduction benefits, the blanket ban fuels illicit trade.
In the Americas, Canada and the United States are open to vaping and other alternatives, while many Latin American countries ban them. New Zealand leads in vaping in the Asia Pacific, while Australia, India, Japan, Thailand, and Vietnam have banned it. Japan, however, is the frontrunner for THP and snus.
In the MENA region, only Lebanon and Saudi Arabia have progressive harm reduction stances, while other countries prohibit alternatives. Nicotine pouches have avoided significant regulatory scrutiny, but their potential depends on recognition for health merits outside of the EU and US.
“With over 8 million lives lost annually to smoking-related diseases, the need for effective anti-smoking measures is more urgent than ever. Nations like Sweden and New Zealand are leading the way by embracing innovative nicotine products in the fight against smoking. Their public policies allowing alternatives have yielded remarkable results, with smoking rates around 5 percent - nearly smoke-free. This success highlights the vital role innovation must play in consigning smoking to history. Policymakers worldwide must follow the example set by these countries, fully harnessing safer products to uproot smoking's toll on global health,” stated Federico N. Fernandez, the CEO of We Are Innovation.
ABOUT WE ARE INNOVATION
We Are Innovation is a dynamic network of individuals and institutions who fervently believe in the power of innovation to drive progress and solve the world’s most pressing problems. With a global presence encompassing over 40 think tanks, foundations, and NGOs, We Are Innovation represents the diverse voices of a global civil society committed to advancing human creativity, embracing new technologies, and promoting innovative solutions. Through our collaborative approach and cutting-edge expertise, we are spearheading transformative change on a global scale. To learn more visit us at https://weareinnovation.global/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402477735/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 22:45:00 CET | Press release
New TOPSwitchGaN ICs more than double power output, reducing system cost, complexity, and design time APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
